Sekar Kathiresan - 30 Jan 2025 Form 3 Insider Report for Maze Therapeutics, Inc. (MAZE)

Role
Director
Signature
/s/ Courtney Phillips, as attorney-in-fact
Issuer symbol
MAZE
Transactions as of
30 Jan 2025
Net transactions value
$0
Form type
3
Filing time
30 Jan 2025, 16:33:09 UTC
Previous filing
10 Jan 2025
Next filing
03 Apr 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding MAZE Common Stock 103,723 30 Jan 2025 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding MAZE Stock Option (Right to Buy) 30 Jan 2025 Common Stock 20,744 $10.42 Direct F1
holding MAZE Stock Option (Right to Buy) 30 Jan 2025 Common Stock 9,086 $10.42 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option vested or vests as to 1/36th of the total award monthly, with the first tranche vesting on May 21, 2022, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date.
F2 The option vested or vests as to 1/36th of the total award monthly, with the first tranche vesting on January 1, 2025, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date.